Multimodal laryngeal preservation: Current data-based opinion;Multimodaler Larynxerhalt: Wege zur besseren Patientenselektion

HNO

Volumn 60, Issue 1, 2012, Pages 19-31

  Dietz, A ^a   Boehm, A ^a   Wichmann, G ^a   Niederwieser, D ^a   Dietzsch, S ^a   Fuchs, M ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Antineoplastic combined chemotherapy protocols; Carcinoma; Larynx; Organ preservation; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CHEMORADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONSERVATIVE TREATMENT; HUMAN; HYPOPHARYNX TUMOR; LARYNX TUMOR; METHODOLOGY; PATIENT SELECTION;

ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; ORGAN SPARING TREATMENTS; PATIENT SELECTION; RADIOTHERAPY, CONFORMAL;

EID: 84856323832     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-011-2416-7     Document Type: Article

References (41)

1. Adelstein D, Saxton J, Lavertu P et al (1997) A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results, chemoradiotherapy vs. radiotherapy. Head Neck 19: 567-575.
2. Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21: 92-98.
3. Pignon JP (2006) Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368: 843-854.
4. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31: 1341-1346.
5. Denis F, Garaud P, Bardet E et al (2003) Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced stage oropharynx carcinoma: Comparison of the LENT/SOMA, RTOG/EORTC, and the NCI-CTC scoring sytems. Int J Radiat Oncol Biol Phys 55: 93-98.
6. Dietz A, Flentje M, Hagen R et al (2010) Docetaxel, cisplatin (TP) and radiation with or without cetuximab in advanced larynx carcinoma (DeLOS II trial). J Clin Oncol 28:(suppl 15): abstr TPS 265).
7. Dietz A, Rudat V, Nollert J et al (2001) Organerhalt beim fortgeschrittenen Larynx-, bzw. Hypopharynxkarzinom durch primäre Radiochemotherapie - Ergebnisse einer multizentrischen Phase-II-Studie. HNO 50: 146-154.
8. Dietz A, Rudat V, Nollert J et al (1998) Das chronische Larynxödem als Spätreaktion nach Radiochemotherapie. HNO 46: 731-738.
9. Dietz A, Boehm A, Horn IS et al (2010) Assay-based response evaluation in head and neck oncology: requirements for better decision making. Eur Arch Otorhinolaryngol 267(4): 483-494 [Epub 2010 Jan 6].
10. Dietz A, Rudat V, Dreyhaupt J et al (2008) Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOSI-trial). Eur Arch Otorhinolaryngol 266(8): 1291-1300 [Epub 2008 Oct 30].
11. Dietz A (2010) Kopf-Hals-Tumoren - Therapie des Larynx-/Hypopharynxkarzinoms unter besonderer Berücksichtigung des Larynxorganerhalts, 2. Aufl. Uni-Med, Bremen.
12. Dietz A, Boehm A, Reiche G et al (2010) Prediction of outcome of TPF with or without cetuximab induction chemotherapy in head and neck squamous cell carcinoma (HNSCC) using the FLAVINO assay. J Clin Oncol 28(suppl 15): abstr 5572).
13. Dische S, Warburton MF, Jones D, Lartigau E (1989) The recording of morbidity related to radiotherapy. Radiat Oncol 16: 103-108.
14. Sant M, Allemani C, Santaquilani M et al (2009) EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45(6): 931-991 [Epub 2009 Jan 24].
15. Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098.
16. Forastiere AA, Maor M, Weber RS et al (2006) Long-term results of Intergroup RTOG 91-11. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24: abstr 5517).
17. Hillman RE, Walsh MJ, Wolf GT et al (1998) Functional outcomes following treatment for advanced laryngeal cancer. Part I - Voice preservation in advanced laryngeal cancer. Part II - Laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group. Ann Otol Rhinol Laryngol Suppl 172: 1-27.
18. Hitt R, Lopez-Pousa A, Martinez-Trufero J et al (2005) Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23(34): 8636-8645.
19. Knecht R, Baghi M, Hambek M et al (2006) TPF induction chemotherapy followed by concurrent radiochemotherapy in the first line therapy of advanced carcinomas of the larynx and pharynx (phase IIb trial). J Clin Oncol 24(Suppl 18): 5562.
20. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM et al (2008) Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 26(22): 3770-3776.
21. Lefebvre JL, Chevalier D, Luboinski B et al (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88: 890-899.
22. Lefebvre J, Pointreau Y (2009) Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study. ASCO (Abstract 2009).
23. Lefebvre JL, Ang KK (2009) Larynx Preservation Consensus Panel. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys 73(5): 1293-1303.
24. Lefebvre J, Pointreau Y, Rolland F et al (2011) Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study. J Clin Oncol 29(suppl): abstr 5501.
25. Mendenhall WM (1998) T3-4 squamous cell carcinoma of the larynx treated with radiation therapy alone. Semin Radiat Oncol 8: 262-269.
26. Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26(21): 3582-3589.
27. Mohide EA, Archibald SD, Tew M et al (1992) Postlaryngectomy quality-of-life dimensions identified by patients and health care professionals. Am J Surg 164: 619-622.
28. Pfreundner L, Hoppe F, Willner J et al (2003) Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas - a possibility for organ preservation. Radiother Oncol 68: 163-170.
29. Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949-955.
30. Pointreau Y, Garaud P, Chapet S et al (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101(7): 498-506.
31. Rosenthal DI, Lewin JS, Eisbruch A (2006) Dysphagia after radiation therapy or chemoradiation for head and neck cancer. J Clin Oncol 24: 2636-2643.
32. Rubin P, Constine LS, Fajardo LF et al (1995) RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 31(5): 1041-1042.
33. Rudat V, Eckel H, Volling P et al (2008) Long-term results of a prospective multicenter phase II study to preserve the larynx function using concomitant boost radiochemotherapy with Carboplatin. Radiother Oncol 89(1): 33-37.
34. Shaker R, Milbarth M, Ren J et al (1995) Deglutitive aspiration with tracheostomy: effect of tracheostomy on the duration of vocal chord closure. Gastroenterology 108: 154-159.
35. Terrell JE, Fisher SG, Wolf GT (1998) Long-term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal Cancer Study Group. Arch Otolaryngol Head Neck Surg 124: 964-971.
36. The Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324: 1685-1690.
37. Trotti A, Bentzen SM (2004) The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 22(1): 19-22.
38. Trotti A, Pajak TF, Gwede CK et al (2007) TAME: development of a new method for summarising adverse events of cancer treatment by the radiation therapy oncology group. Lancet Oncol 8(7): 613-624.
39. Urba S, Wolf G, Eisbruch A et al (2006) Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 24: 593-598.
40. Worden FP, Wolf G, Eisbruch A et al (2007) Chemo-selection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma. J Clin Oncol 25(Suppl 18): 6005 (ASCO Annual Meeting 2007).
41. Zhang HH, Meyer RR, Shi L, D'Souza WD (2010) The minimum knowledge base for predicting organ-at-risk dose-volume levels and plan-related complications in IMRT planning. Phys Med Biol 55(7): 1935-1947.